Cas No.: | 1038395-65-1 |
Chemical Name: | 5-[4-[2-(4-Morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)-2-pyridineacetamide hydrochloride |
Synonyms: | 5-[4-[2-(4-Morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)-2-pyridineacetamide hydrochloride;KX2-391;KX2-391 (dihydrochloride);N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide,dihydrochloride;CS-0455;KX2-391 2HCl;KX2-391 dihydrochloride;KW-2449 HCl;(E)-(4-(2-(1H-indazol-3-yl)vinyl)phenyl)(piperazin-1-yl)methanone hydrochloride;5-[4-[2-(4-Morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)-2-pyridineacetamide hydrochlorideKX2-391 (dihydrochloride);Tirbanibulin dihydrochloride |
SMILES: | O=C(CC1=NC=C(C2=CC=C(OCCN3CCOCC3)C=C2)C=C1)NCC4=CC=CC=C4.Cl.Cl |
Formula: | C26H29N3O3.2[HCl] |
M.Wt: | 504.44864 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | A highly selective, non-ATP competitive substrate-pocket-directed Src/pretubulin inhibitor; inhibits c-Src kinase with GI50s of 1.34 uM and 2.30 μM in NIH3T3/c-Src527F and SYF/c-Src527F cells, respectively; causes microtubule disruption in tumor cells; orally active.Solid TumorsPhase 2 Clinical |